BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) insider Lai Wang sold 700 shares of the stock in a transaction dated Friday, July 18th. The stock was sold at an average price of $300.00, for a total transaction of $210,000.00. Following the transaction, the insider directly owned 1,023,529 shares in the company, valued at $307,058,700. The trade was a 0.07% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link.
Lai Wang also recently made the following trade(s):
- On Monday, June 23rd, Lai Wang sold 1,028 shares of BeOne Medicines stock. The stock was sold at an average price of $260.00, for a total transaction of $267,280.00.
- On Tuesday, June 17th, Lai Wang sold 470 shares of BeOne Medicines stock. The stock was sold at an average price of $251.37, for a total transaction of $118,143.90.
- On Monday, June 16th, Lai Wang sold 1,177 shares of BeOne Medicines stock. The stock was sold at an average price of $266.40, for a total transaction of $313,552.80.
- On Friday, June 6th, Lai Wang sold 1,402 shares of BeOne Medicines stock. The stock was sold at an average price of $252.39, for a total transaction of $353,850.78.
BeOne Medicines Price Performance
Shares of BeOne Medicines stock traded down $4.99 on Friday, hitting $291.47. The company had a trading volume of 171,226 shares, compared to its average volume of 369,628. The business has a 50-day simple moving average of $257.72. The company has a current ratio of 1.96, a quick ratio of 1.71 and a debt-to-equity ratio of 0.05. The stock has a market cap of $31.95 billion, a P/E ratio of -78.35 and a beta of 0.28. BeOne Medicines Ltd. - Sponsored ADR has a 52 week low of $155.75 and a 52 week high of $300.00.
BeOne Medicines (NASDAQ:ONC - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $1.22 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $1.93. The business had revenue of $1.12 billion during the quarter, compared to analysts' expectations of $1.12 billion. BeOne Medicines had a negative net margin of 9.40% and a negative return on equity of 7.55%. On average, equities research analysts predict that BeOne Medicines Ltd. - Sponsored ADR will post -5.82 earnings per share for the current fiscal year.
Analyst Ratings Changes
ONC has been the topic of several research reports. TD Securities reiterated a "buy" rating and set a $334.00 price objective on shares of BeOne Medicines in a research note on Thursday, April 24th. Royal Bank Of Canada raised their price target on shares of BeOne Medicines from $311.00 to $349.00 and gave the company an "outperform" rating in a research note on Wednesday, July 16th. Morgan Stanley raised their price target on shares of BeOne Medicines from $313.00 to $330.00 and gave the company an "overweight" rating in a research note on Friday, June 27th. Wall Street Zen upgraded shares of BeOne Medicines from a "hold" rating to a "buy" rating in a research note on Saturday. Finally, Guggenheim raised their price target on shares of BeOne Medicines from $348.00 to $350.00 and gave the company a "buy" rating in a research note on Thursday, May 8th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $327.56.
Get Our Latest Report on ONC
Institutional Trading of BeOne Medicines
A number of large investors have recently added to or reduced their stakes in the business. Sequoia Financial Advisors LLC bought a new stake in BeOne Medicines during the second quarter worth approximately $298,000. Yousif Capital Management LLC bought a new stake in BeOne Medicines during the second quarter worth approximately $368,000. Vanguard Personalized Indexing Management LLC bought a new stake in BeOne Medicines during the second quarter worth approximately $537,000. Blue Trust Inc. bought a new stake in BeOne Medicines during the second quarter worth approximately $210,000. Finally, IFP Advisors Inc bought a new stake in BeOne Medicines during the second quarter worth approximately $243,000. 48.55% of the stock is currently owned by institutional investors.
BeOne Medicines Company Profile
(
Get Free Report)
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.
Featured Stories
Before you consider BeOne Medicines, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BeOne Medicines wasn't on the list.
While BeOne Medicines currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
